Brief: Immunotech Biopharm Announces IND Application Approval For CAR-T-19 Injection By CDE
Dec 28 (Reuters) - Immunotech Biopharm Ltd 6978.HK :
* CAR-T-19 INJECTION GOT APPROVAL OF IND APPLICATION FOR
CLINICAL
TRIALS FROM CENTRE FOR DRUG EVALUATION OF NMPA
Source text https://www1.hkexnews.hk/listedco/listconews/sehk/2020/1228/2020122801505.pdf
Further company coverage: 6978.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immunotech Biopharm
See all newsBrief: Immunotech Biopharm Gets Approval In Sept 2025 For Clinical Translational Application Of Atl In Hainan
Brief: Immunotech Biopharm Receives Notice Of Rejection For Conditional New Drug Application For EAL Dated 27 April 2026
Brief: Trading In Shares Of Immunotech Biopharm Will Be Halted At 1:00 PM On April 28, HKEX Says
Brief: Immunotech Biopharm Posts Loss And Total Comprehensive Expense For Year Attributable Rmb230.8 Million
Brief: Immunotech Biopharm Subscribes To Structured Deposit Product With Investment Value Of RMB50 MLN